Your browser doesn't support javascript.
loading
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster, Stephen J; Tam, Constantine S; Borchmann, Peter; Worel, Nina; McGuirk, Joseph P; Holte, Harald; Waller, Edmund K; Jaglowski, Samantha; Bishop, Michael R; Damon, Lloyd E; Foley, Stephen Ronan; Westin, Jason R; Fleury, Isabelle; Ho, P Joy; Mielke, Stephan; Teshima, Takanori; Janakiram, Murali; Hsu, Jing-Mei; Izutsu, Koji; Kersten, Marie José; Ghosh, Monalisa; Wagner-Johnston, Nina; Kato, Koji; Corradini, Paolo; Martinez-Prieto, Marcela; Han, Xia; Tiwari, Ranjan; Salles, Gilles; Maziarz, Richard T.
Afiliação
  • Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: stephen.schuster@pennmedicine.upenn.edu.
  • Tam CS; Peter MacCallum Cancer Center, Royal Melbourne Hospital and University of Melbourne, Melbourne, VIC, Australia.
  • Borchmann P; Clinic I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
  • Worel N; Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.
  • McGuirk JP; Department of Internal Medicine, The University of Kansas Health System, Kansas City, KS, USA.
  • Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway.
  • Waller EK; Bone Marrow and Stem Cell Transplant Center, Emory University Winship Cancer Institute, Atlanta, GA, USA.
  • Jaglowski S; Blood and Marrow Transplant Program, James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Bishop MR; Hematopoietic Cellular Therapy Program, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
  • Damon LE; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Foley SR; Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
  • Westin JR; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
  • Fleury I; Department of Lymphoma and Myeloma, Maisonneuve-Rosement Hospital, University of Montreal, Montreal, QC, Canada.
  • Ho PJ; Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW, Australia.
  • Mielke S; Department of Medicine II, University of Würzburg Medical Center, Würzburg, Germany; Department of Laboratory Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Department of Medicine, Huddinge, Karolinska Institutet and Karolinska University Hospital, Stockholm,
  • Teshima T; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.
  • Janakiram M; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN, USA.
  • Hsu JM; Department of Medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, New York, NY, USA.
  • Izutsu K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
  • Kersten MJ; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Ghosh M; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Wagner-Johnston N; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.
  • Kato K; Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
  • Corradini P; Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy.
  • Martinez-Prieto M; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Han X; Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Tiwari R; Novartis Healthcare, Hyderabad, India.
  • Salles G; Department of Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France.
  • Maziarz RT; Center for Hematologic Malignancies, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USA.
Lancet Oncol ; 22(10): 1403-1415, 2021 10.
Article em En | MEDLINE | ID: mdl-34516954
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Imunoterapia Adotiva / Linfoma Difuso de Grandes Células B Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Asia / Europa / Oceania Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Linfócitos T / Imunoterapia Adotiva / Linfoma Difuso de Grandes Células B Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte / Asia / Europa / Oceania Idioma: En Ano de publicação: 2021 Tipo de documento: Article